Stem Cell-Derived Platelet Product Clears China Clinical Entry

Company Suzhou Xueji Bio Event Type Regulatory Clinical Clearance (Implied NMPA Permission) Modality Stem Cell-Derived Allogeneic Platelet Injection Asset PLT-001 Target Not Applicable (Cell Therapy Replacement Product) Disease Area Thrombocytopenia Associated with Cancer Treatment and Hematologic Malignancy Summary Suzhou Xueji Bio reported implied NMPA clinical…